IP Library › Granted Patent US 12,398,145
Granted Patent B2
US 12,398,145 · App. 18/126,676 · Granted Aug 26, 2025

Bicyclic urea kinase inhibitors and uses thereof

Inventors: Nathanael S. Gray (Stanford, CA); Yanke Liang (Belmont, MA); Hwan Geun Choi (Chestnut Hill, MA); Thomas Sundberg (Boston, MA); Alykhan Shamji (Somerville, MA); Ramnik Xavier (Brookline, MA); David E. Fisher (Newton, MA); Nisma Mujahid (Spencerport, NY)
Assignees: THE BROAD INSTITUTE, INC.; THE GENERAL HOSPITAL CORPORATION; DANA-FARBER CANCER INSTITUTE, INC.
C07D487/04A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,398,145
App. No.
18/126,676
Granted
Aug 26, 2025
Kind
B2
Abstract

The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.

Claims (83)

1. A compound of Formula (III):

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof,

wherein:

R L is substituted or unsubstituted alkyl;

Ring C is unsubstituted phenyl or of the formula:

each instance of R B1 is independently halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR a , —N(R d ) 2 , —SR a , —CN, —SCN, —C(═NR d )R a , —C(═NR d )OR a , —C(═NR d )N(R d ) 2 , —C(═O)R a , —C(═O)OR a , —C(═O)N(R d ) 2 , —NO 2 , —NR d C(═O)R a , —NR d C(═O)OR a , —NR d C(═O)N(R a ) 2 , —OC(═O)R a , —OC(═O)OR a , or —OC(═O)N(R d ) 2 ;

each instance of R a is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom;

each instance of R d is independently hydrogen, —C(═O)R a , substituted or unsubstituted C 1-6 alkyl, or a nitrogen protecting group, or optionally two instances of R d are taken together with their intervening atoms to form a substituted or unsubstituted heterocyclic or substituted or unsubstituted heteroaryl ring;

R C is hydrogen, halogen, or substituted or unsubstituted C 1-6 alkyl;

R D is hydrogen, halogen, or substituted or unsubstituted C 1-6 alkyl;

R E is hydrogen, halogen, or substituted or unsubstituted C 1-6 alkyl;

R F is hydrogen, substituted or unsubstituted C 1-6 alkyl, or a nitrogen protecting group;

Ring A is substituted or unsubstituted phenyl; substituted or unsubstituted, polycyclic aryl; substituted or unsubstituted, 5- or 6-membered, monocyclic heteroaryl; or substituted or unsubstituted, polycyclic heteroaryl;

each instance of R G is independently halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR a , —N(R b ) 2 , —SR a , —CN, —SCN, —C(═NR b )R a , —C(═NR b )OR a , —C(═NR a )N(R a ) 2 , —C(═O)R a , —C(═O)OR a , —C(═O)N(R a ) 2 , —NO 2 , —NR b C(═O)R a , —NR b C(═O)OR a , —NR b C(═O)N(R a ) 2 , —OC(═O)R a , —OC(═O)OR a , or —OC(═O)N(R b ) 2 ;

each instance of R b is independently hydrogen, substituted or unsubstituted C 1-6 alkyl, or a nitrogen protecting group, or optionally two instances of R b are taken together with their intervening atoms to form a substituted or unsubstituted heterocyclic or substituted or unsubstituted heteroaryl ring;

n is 0, 1, 2, 3, or 4, as valency permits;

R K is unsubstituted methyl, substituted or unsubstituted heterocyclyl, —OR a , or —N(R c ) 2 , wherein each instance of R c is independently hydrogen, substituted or unsubstituted C 1-6 alkyl, or a nitrogen protecting group, or optionally two instances of R c are taken together with their intervening atoms to form a substituted or unsubstituted heterocyclic or substituted or unsubstituted heteroaryl ring; and

R Y is substituted phenyl; and

wherein each instance of the optional carbon atom substituent is independently halogen, —CN, —NO 2 , —N 3 , —SO 2 H, —SO 3 H, —OH, —OR aa , —ON(R bb ) 2 , —N(R bb ) 2 , —N(R bb ) 3 + X − , —N(OR cc )R bb , —SH, —SR aa , —SSR cc , —C(═O)R aa , —CO 2 H, —CHO, —C(OR cc ) 2 , —CO 2 R aa , —OC(═O)R aa , —OCO 2 R aa , —C(═O)N(R bb ) 2 , —OC(═O)N(R bb ) 2 , —NR bb C(═O)R aa , —NR bb CO 2 R aa , —NR bb C(═O)N(R bb ) 2 , —C(═NR bb )R a , —C(═NR bb )OR aa , —OC(═NR bb )R aa , —OC(═NR bb )OR aa , —C(═NR bb )N(R bb ) 2 , —OC(═NR bb )N(R bb ) 2 , —NR bb C(═NR bb )N(R bb ) 2 , —C(═O)NR bb SO 2 R aa , —NR bb SO 2 R aa , —SO 2 N(R bb ) 2 , —SO 2 R aa , —SO 2 OR a , —OSO 2 R aa , —S(═O)R aa , —OS(═O)R aa , —Si(R aa ) 3 , —OSi(R aa ) 3 , —C(═S)N(R bb ) 2 , —C(═O)SR aa , —C(═S)SR aa , —SC(═S)SR aa , —SC(═O)SR aa , —OC(═O)SR aa , —SC(═O)OR aa , —SC(═O)R aa , —P(═O)(R aa ) 2 , —P(═O)(OR cc ) 2 , —OP(═O)(R aa ) 2 , —OP(═O)(OR cc ) 2 , —P(═O)(N(R bb ) 2 ) 2 , —OP(═O)(N(R bb ) 2 ) 2 , —NR bb P(═O)(R aa ) 2 , —NR bb P(═O)(OR cc ) 2 , —NR bb P(═O)(N(R bb ) 2 ) 2 , —P(R cc ) 2 , —P(OR cc ) 2 , —P(R cc ) 3 + X − , —P(OR cc ) 3 + X − , —P(R cc ) 4 , —P(OR cc ) 4 , —OP(R cc ) 2 , —OP(R cc ) 3 + X − , —OP(OR cc ) 2 , —OP(OR cc ) 3 + X − , —OP(R cc ) 4 , —OP(OR cc ) 4 , —B(R′) 2 , —B(OR cc ) 2 , BR aa (OR cc ), C 1-10 alkyl, C 1-10 perhaloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, heteroC 1-10 alkyl, heteroC 2-10 alkenyl, heteroC 2-10 alkynyl, C 3-10 carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, or 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups;

or two geminal hydrogens on a carbon atom are replaced with the group ═O, ═S, ═NN(R bb ) 2 , ═NNR bb C(═O)R aa , ═NNR bb C(O)OR aa , ═NN bb S(═O) 2 R aa , ═NR bb , or ═NOR cc ;

each instance of R aa is, independently, selected from C 1-10 alkyl, C 1-10 perhaloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, heteroC 1-10 alkyl, heteroC 2-10 alkenyl, heteroC 2-10 alkynyl, C 3-10 carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, or 5-14 membered heteroaryl, or two R aa groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups;

each instance of R bb is, independently, selected from hydrogen, —OH, —OR aa , —N(R cc ) 2 , —CN, —C(═O)R aa , —C(═O)N(N cc ) 2 , —CO 2 R aa , —SO 2 R aa , —C(═NR cc )OR aa , —C(═NR cc )N(R cc ) 2 , —SO 2 N(R cc ) 2 , —SO 2 R cc , —SO 2 OR cc , —SOR aa , —C(═S)N(N cc ) 2 , —C(═O)SR cc , —C(═S)SR cc , —P(═O)(R cc ) 2 , —P(═O)(OR cc ) 2 , —P(═O)(N(R cc ) 2 ) 2 , C 1-10 alkyl, C 1-10 perhaloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, heteroC 1-10 alkyl, heteroC 2-10 alkenyl, heteroC 2-10 alkynyl, C 3-10 carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, or 5-14 membered heteroaryl, or two R bb groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups;

each instance of R cc is, independently, selected from C 1-10 alkyl, C 1-10 perhaloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, heteroC 1-10 alkyl, heteroC 2-10 alkenyl, heteroC 2-10 alkynyl, C 3-10 carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, or 5-14 membered heteroaryl, or two R cc groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups;

each instance of R dd is, independently, selected from halogen, —CN, —NO 2 , —N 3 , —SO 2 H, —SO 3 H, —OH, —OR ee , —ON(R ff ) 2 , —N(R ff ) 2 , —N(R) 3 + X − , —N(OR ee )R ee , —SH, —SR ee , —SSR ee , —C(═O)R ee , —CO 2 H, —CO 2 R ee , —OC(═O)R ee , —OCO 2 R ee , —C(═O)N(R ff ) 2 , —OC(═O)N(R ff ) 2 , —NR ff C(═O)R ee , —NRCO 2 R ee , —NR ff C(═O)N(R ff ) 2 , —C(═NR ff )OR ee , —OC(═NR ff )R ee , —OC(═NR ff )OR ee , —C(═NR ff )N(R ff ) 2 , —OC(═NR ff )N(R ff ) 2 , —NR ff C(═NR ff )N(R ff ) 2 , —NR ff SO 2 R ee , —SO 2 N(R ff ) 2 , —SO 2 R ee , —SO 2 OR ee , —OSO 2 R ee , —S(═O)R ee , —Si(R ee ) 3 , —OSi(R ee ) 3 , —C(═S)N(R ff ) 2 , —C(═O)SR ee , —C(═S)SR ee , —SC(═S)SR ee , —P(═O)(OR ee ) 2 , —OP(═O)(R ee ) 2 , —OP(═O)(OR ee ) 2 , —OP(═O)(OR ee ) 2 , C 1-6 alkyl, C 1-6 perhaloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, heteroC 1-6 alkyl, heteroC 2-6 alkenyl, heteroC 2-6 alkynyl, C 3-10 carbocyclyl, 3-10 membered heterocyclyl, C 6-10 aryl, or 5-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R gg groups, or two geminal R dd substituents can be joined to form ═O or ═S;

each instance of R ee is, independently, selected from C 1-6 alkyl, C 1-6 perhaloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, heteroC 1-6 alkyl, heteroC 2-6 alkenyl, heteroC 2-6 alkynyl, C 3-10 carbocyclyl, C 6-10 aryl, 3-10 membered heterocyclyl, or 5-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R gg groups;

each instance of R ff is, independently, selected from hydrogen, C 1-6 alkyl, C 1-6 perhaloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, heteroC 1-6 alkyl, heteroC 2-6 alkenyl, heteroC 2-6 alkynyl, C 3-10 carbocyclyl, 3-10 membered heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl, or two R groups are joined to form a 3-10 membered heterocyclyl or 5-10 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R gg groups;

each instance of R gg is, independently, halogen, —CN, —NO 2 , —N 3 , —SO 2 H, —SO 3 H, —OH, —OC 1-6 alkyl, —ON(C 1-6 alkyl) 2 , —N(C 1-6 alkyl) 2 , —N(C 1-6 alkyl) 3 + X − , —NH(C 1-6 alkyl) 2 + X − , —NH 2 (C 1-6 alkyl) + X − , —NH 3 + X − , —N(OC 1-6 alkyl)C 1-6 alkyl, —N(OH)(C 1-6 alkyl), —NH(OH), —SH, —SC 1-6 alkyl, —SSC 1-6 alkyl, —C(═O)C 1-6 alkyl, —CO 2 H, —CO 2 (C 1-6 alkyl), —OC(═O)(C 1-6 alkyl), —OCO 2 (C 1-6 alkyl), —C(═O)N 2 , —OC(═O)N(C 1-6 alkyl) 2 , —OC(═O)NH(C 1-6 alkyl), —NHC(═O)(C 1-6 alkyl), —N(C 1-6 alkyl)C(═O)(C 1-6 alkyl), —NHCO 2 (C 1-6 alkyl), —NHC(═O)N(C 1-6 alkyl) 2 , —NHC(═O)NH(C 1-6 alkyl), —NHC(═O)NH 2 , —C(═NH)O(C 1-6 alkyl), —OC(═NH)(C 1-6 alkyl), —OC(═NH)OC 1-6 alkyl, —C(═NH)N(C 1-6 alkyl) 2 , —C(═NH)NH(C 1-6 alkyl), —C(═NH)NH 2 , —OC(═NH)N(C 1-6 alkyl) 2 , —OC(NH)NH(C 1-6 alkyl), —OC(NH)NH 2 , —NHC(NH)N(C 1-6 alkyl) 2 , —NHC(═NH)NH 2 , —NHSO 2 (C 1-6 alkyl), —SO 2 N(C 1-6 alkyl) 2 , —SO 2 NH(C 1-6 alkyl), —SO 2 NH 2 , —SO 2 C 1-6 alkyl, —SO 2 OC 1-6 alkyl, —OSO 2 C 1-6 alkyl, —SOC 1-6 alkyl, —Si(C 1-6 alkyl) 3 , —OSi(C 1-6 alkyl) 3 , —C(═S)N(C 1-6 alkyl) 2 , —C(═S)NH(C 1-6 alkyl), —C(═S)NH 2 , —C(═O)S(C 1-6 alkyl), —C(═S)SC 1-6 alkyl, —SC(═S)SC 1-6 alkyl, —P(═O)(OC 1-6 alkyl) 2 , —P(═O)(C 1-6 alkyl) 2 , —OP(═O)(C 1-6 alkyl) 2 , —OP(═O)(OC 1-6 alkyl) 2 , C 1-6 alkyl, C 1-6 perhaloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, heteroC 1-6 alkyl, heteroC 2-6 alkenyl, heteroC 2-6 alkynyl, C 3-10 carbocyclyl, C 6-10 aryl, 3-10 membered heterocyclyl, and 5-10 membered heteroaryl; or two geminal R gg substituents can be joined to form ═O or ═S;

wherein X − is a counterion;

each instance of the optional nitrogen atom substituent is independently hydrogen, —OH, —OR aa , —N(R cc ) 2 , —CN, —C(═O)R aa , —C(═O)N(R cc ) 2 , —CO 2 R aa , —SO 2 R aa , —C(═NR bb )R aa , —C(═NR cc )OR aa , —C(═NR cc )N(R cc ) 2 , —SO 2 N(R cc ) 2 , —SO 2 R cc , —SO 2 OR cc , —SOR aa , —C(═S)N(R cc ) 2 , —C(═O)SR cc , —C(═S)SR cc , —P(═O)(OR cc ) 2 , —P(═O)(R cc ) 2 , —P(═O)(N(R cc ) 2 ) 2 , C 1-10 alkyl, C 1-10 perhaloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, heteroC 1-10 alkyl, heteroC 2-10 alkenyl, heteroC 2-10 alkynyl, C 3-10 carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, 5-14 membered heteroaryl, or a nitrogen protecting group, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups; and

each instance of the optional sulfur atom substituent is independently substituted or unsubstituted C 1-6 alkyl, —C(═O)R aa , —CO 2 R aa , —C(═O)N(R bb ) 2 , or a sulfur protecting group.

2. The compound of claim 1 , wherein R L is substituted or unsubstituted C 1-6 alkyl.

3. The compound of claim 1 , wherein R L is Me, Et, iPr, or Pr.

4. The compound of claim 1 , wherein Ring C is unsubstituted phenyl.

5. The compound of claim 1 , wherein Ring C is of the formula:

6. The compound of claim 1 , wherein at least one instance of R B1 is halogen or substituted or unsubstituted C 1-6 alkyl, or —N(R d ) 2 , wherein each instance of R d is hydrogen or —C(═O)R a .

7. The compound of claim 5 , wherein Ring C is of the formula:

8. The compound of claim 1 , wherein R K is substituted or unsubstituted heterocyclyl.

9. The compound of claim 8 , wherein R K is substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl, or substituted or unsubstituted piperazinyl.

10. The compound of claim 1 , wherein R K is —N(R c ) 2 .

11. The compound of claim 10 , wherein each instance of R c is substituted or unsubstituted C 1-6 alkyl.

12. The compound of claim 1 , wherein at least one instance of R G is —OR a , wherein R a is substituted or unsubstituted C 1-6 alkyl.

13. The compound of claim 1 , wherein each one of R C and R D is hydrogen.

14. The compound of claim 1 , wherein one of R C and R D is hydrogen, and the other of R C and R D is substituted or unsubstituted C 1-6 alkyl.

15. The compound of claim 1 , wherein R E is hydrogen.

16. The compound of claim 1 , wherein R F is hydrogen.

17. The compound of claim 1 , wherein Ring A is substituted or unsubstituted phenyl.

18. The compound of claim 1 , wherein Ring A is substituted or unsubstituted, 5- or 6-membered, monocyclic heteroaryl.

19. The compound of claim 18 , wherein Ring A is substituted or unsubstituted pyridyl or substituted or unsubstituted pyrazolyl.

20. The compound of claim 1 , wherein n is 1.

21. The compound of claim 1 , wherein n is 2.

22. The compound of claim 1 , wherein at least one instance of R G is halogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted heterocyclyl, or —OR a .

23. The compound of claim 1 , wherein n is 0.

24. The compound of claim 1 , wherein R C is hydrogen.

25. The compound of claim 1 , wherein R D is hydrogen.

26. The compound of claim 1 , wherein R E is hydrogen.

27. The compound of claim 1 , wherein R F is hydrogen.

28. The compound of claim 1 , wherein R C , R D , R E , and R F are each hydrogen.

29. The compound of claim 1 , wherein Ring C is unsubstituted phenyl, R C , R D , R E , and R F are each hydrogen, n is 0, R L is substituted or unsubstituted C 1-6 alkyl, and R K is substituted or unsubstituted piperidinyl, or substituted or unsubstituted piperazinyl.

30. The compound of claim 1 , wherein Ring C is of the formula:

 R C , R D , R E , and R F are each hydrogen, R G is —OR a , methyl, or ethyl, R L is substituted or unsubstituted C 1-6 alkyl, and R K is substituted or unsubstituted piperidinyl, or substituted or unsubstituted piperazinyl.

31. The compound of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

32. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, and optionally a pharmaceutically acceptable excipient.

33. The pharmaceutical composition of claim 32 further comprising an additional pharmaceutical agent.

34. The pharmaceutical composition of claim 33 , wherein the additional pharmaceutical agent is a kinase inhibitor.

35. The pharmaceutical composition of claim 34 , wherein the additional pharmaceutical agent is a salt-inducible kinase (SIK) inhibitor or a salt-inducible kinase 2 (SIK2) inhibitor.

36. A method of treating a disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein the disease is associated with aberrant activity of a protein kinase.

37. The method of claim 36 , wherein the protein kinase is a salt-inducible kinase (SIK) or salt-inducible kinase 2 (SIK2).

38. The method of claim 36 , wherein the disease is a genetic disease, a proliferative disease, cancer, benign neoplasm, pathological angiogenesis, an inflammatory disease, a musculoskeletal disease, an autoimmune disease, a hematological disease, a neurological disease, a painful condition, a psychiatric disorder, or a metabolic disorder.

39. A kit comprising:

a compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof; and

instructions for using the compound or pharmaceutical composition.

40. The compound of claim 1 , which is

(YKL-06-029), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof.

41. A pharmaceutical composition comprising a compound of claim 40 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, and optionally a pharmaceutically acceptable excipient.

42. A method of treating a disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 40 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein the disease is associated with aberrant activity of a protein kinase.

43. The method of claim 42 , wherein the protein kinase is a salt-inducible kinase (SIK) or salt-inducible kinase 2 (SIK2).

44. The method of claim 42 , wherein the disease is a genetic disease, a proliferative disease, cancer, benign neoplasm, pathological angiogenesis, an inflammatory disease, a musculoskeletal disease, an autoimmune disease, a hematological disease, a neurological disease, a painful condition, a psychiatric disorder, or a metabolic disorder.

45. A kit comprising:

a compound of claim 40 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof; and

instructions for using the compound or pharmaceutical composition.

46. The pharmaceutical composition of claim 32 , further comprising a pharmaceutically acceptable excipient and is in the form of a tablet, dragee, capsule, pill, or granule.

47. The pharmaceutical composition of claim 32 , further comprising a pharmaceutically acceptable excipient and is in the form of an ointment, paste, cream, lotion, gel, powder, solution, spray, inhalant, or patch.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2023
From: FISHER, DAVID E.; MUJAHID, NISMA; XAVIER, RAMNIK
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 063143/0965 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2023
From: GRAY, NATHANAEL S.; LIANG, YANKE; CHOI, HWAN GEUN
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 063144/0052 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2023
From: SUNDBERG, THOMAS; SHAMJI, ALYKHAN
To: THE BROAD INSTITUTE, INC.
Reel/Frame 063144/0156 →
Continuity (4)
Continuation 16953984 · Nov 20, 2020
Continuation 16315438
Provisional Application 62358524 · Jul 5, 2016
Related Publication 20230234959A1 · Jul 27, 2023
References Cited (275)
US 6150373A · Harris et al. · 2000 [cited by applicant]
US 6217875B1 · Murai et al. · 2001 [cited by applicant]
US 7084270B2 · Chen et al. · 2006 [cited by applicant]
US 7112676B2 · Dermatakis et al. · 2006 [cited by applicant]
US 7312225B2 · Luecking et al. · 2007 [cited by applicant]
US 8921336B2 · Gray et al. · 2014 [cited by applicant]
US 9586936B2 · Sim et al. · 2017 [cited by applicant]
US 9663524B2 · D'Agostino et al. · 2017 [cited by applicant]
US 9670165B2 · Cohen et al. · 2017 [cited by applicant]
US 9783504B2 · Gray et al. · 2017 [cited by applicant]
US 9925188B2 · Charifson et al. · 2018 [cited by applicant]
US 10233157B2 · Cohen et al. · 2019 [cited by applicant]
US 10265321B2 · Shamji et al. · 2019 [cited by applicant]
US 10287268B2 · Gray et al. · 2019 [cited by applicant]
US 10457691B2 · Gray et al. · 2019 [cited by applicant]
US 10954242B2 · Gray · 2021 [cited by examiner]
US 11725011B2 · Gray · 2023 [cited by examiner]
US 20040204427A1 · Chen et al. · 2004 [cited by applicant]
US 20050026914A1 · Buchanan et al. · 2005 [cited by applicant]
US 20050202001A1 · Koo et al. · 2005 [cited by applicant]
US 20060258687A1 · Boehm et al. · 2006 [cited by applicant]
US 20070225286A1 · Ren et al. · 2007 [cited by applicant]
US 20080249079A1 · Chen et al. · 2008 [cited by applicant]
US 20090137804A1 · Ding et al. · 2009 [cited by applicant]
US 20100056524A1 · McIver et al. · 2010 [cited by applicant]
US 20110086858A1 · Wang et al. · 2011 [cited by applicant]
US 20110207711A1 · Katz et al. · 2011 [cited by applicant]
US 20150203818A1 · Mountford et al. · 2015 [cited by applicant]
US 20170204082A1 · Gray et al. · 2017 [cited by applicant]
US 20170204116A1 · Gray et al. · 2017 [cited by applicant]
US 20170224700A1 · Shamji et al. · 2017 [cited by applicant]
US 20170342036A1 · Cohen et al. · 2017 [cited by applicant]
US 20180221379A1 · Shamji et al. · 2018 [cited by applicant]
US 20190315752A1 · Gray et al. · 2019 [cited by applicant]
US 20190343842A1 · Shamji et al. · 2019 [cited by applicant]
US 20190367487A1 · Gray et al. · 2019 [cited by applicant]
US 20200179387A1 · Wein et al. · 2020 [cited by applicant]
US 20200253981A1 · Fisher et al. · 2020 [cited by applicant]
CN 104418860 · 2006 [cited by applicant]
CN 104482860 · 2015 [cited by applicant]
EP 1544295 · 2005 [cited by applicant]
EP 2746283 · 2014 [cited by applicant]
JP 2002516327 · 2002 [cited by applicant]
JP 2002528455 · 2002 [cited by applicant]
JP 2006522756 · 2006 [cited by applicant]
JP 2007500725 · 2007 [cited by applicant]
JP 2008510690 · 2008 [cited by applicant]
WO WO1999061444 · 1999 [cited by applicant]
WO WO2000024744 · 2000 [cited by applicant]
WO WO2004041821 · 2004 [cited by applicant]
WO WO2004041822 · 2004 [cited by applicant]
WO WO2004048343 · 2004 [cited by applicant]
WO WO2004089955 · 2004 [cited by applicant]
WO WO2005009443 · 2005 [cited by applicant]
WO WO2005009978 · 2005 [cited by applicant]
WO WO2005011597 · 2005 [cited by applicant]
WO WO2005123719 · 2005 [cited by applicant]
WO WO2006000420 · 2006 [cited by applicant]
WO WO2006024486 · 2006 [cited by applicant]
WO WO2006024545 · 2006 [cited by applicant]
WO WO2006135824 · 2006 [cited by applicant]
WO WO2007071752 · 2007 [cited by applicant]
WO WO2007136465 · 2007 [cited by applicant]
WO WO2008060248 · 2008 [cited by applicant]
WO WO2009073153 · 2009 [cited by applicant]
WO WO2009122180 · 2009 [cited by applicant]
WO WO2009152027 · 2009 [cited by applicant]
WO WO2010067888 · 2010 [cited by applicant]
WO WO2013045653 · 2013 [cited by applicant]
WO WO2013074986 · 2013 [cited by applicant]
WO WO2013136070 · 2013 [cited by applicant]
WO WO2014093383 · 2014 [cited by applicant]
WO WO2014138485 · 2014 [cited by applicant]
WO WO2014140313 · 2014 [cited by applicant]
WO WO2014144737 · 2014 [cited by applicant]
WO WO2015006492 · 2015 [cited by applicant]
WO WO2016014542 · 2016 [cited by applicant]
WO WO2016014551 · 2016 [cited by applicant]
WO WO2016023014 · 2016 [cited by applicant]
WO WO2018009544 · 2018 [cited by applicant]
WO WO2018053373 · 2018 [cited by applicant]
WO WO2018160774 · 2018 [cited by applicant]
Extended European Search Report for EP 15824907.8, mailed Jan. 2, 2018. [cited by applicant]
Extended European Search Report for EP 15824975.5, mailed Nov. 27, 2017. [cited by applicant]
Extended European Search Report for EP 15829427.2, mailed May 14, 2018. [cited by applicant]
Extended European Search Report for EP 18760857.5, mailed Nov. 12, 2020. [cited by applicant]
Extended European Search Report for EP 19164054.9, mailed Jul. 31, 2019. [cited by applicant]
International Preliminary Report on Patentability for PCT/GB2013/050618, mailed Sep. 25, 2014. [cited by applicant]
International Preliminary Report on Patentability for PCT/US2015/041360 mailed Feb. 2, 2017. [cited by applicant]
International Preliminary Report on Patentability for PCT/US2015/044387, mailed Feb. 23, 2017. [cited by applicant]
International Preliminary Report on Patentability for PCT/US2015/041348 mailed Feb. 2, 2017. [cited by applicant]
International Preliminary Report on Patentability for PCT/US2017/040722, mailed Jan. 17, 2019. [cited by applicant]
International Preliminary Report on Patentability for PCT/US2017/051937, mailed Mar. 28, 2019. [cited by applicant]
International Preliminary Report on Patentability for PCT/US2018/020335, mailed Sep. 12, 2019. [cited by applicant]
International Search Report and Written Opinion for PCT/GB2013/050618, mailed May 17, 2013. [cited by applicant]
International Search Report and Written Opinion for PCT/US2015/041360 mailed Dec. 15, 2015. [cited by applicant]
International Search Report and Written Opinion for PCT/US2015/044387, mailed Mar. 25, 2016. [cited by applicant]
International Search Report and Written Opinion for PCT/US2015/41348 mailed Oct. 28, 2015. [cited by applicant]
International Search Report and Written Opinion for PCT/US2017/040722, mailed Dec. 12, 2017. [cited by applicant]
International Search Report and Written Opinion for PCT/US2017/051937, mailed Dec. 28, 2017. [cited by applicant]
International Search Report and Written Opinion for PCT/US2018/020335, mailed May 17, 2018. [cited by applicant]
Invitation to Pay Additional Fees for PCT/US2015/041360 mailed Sep. 24, 2015. [cited by applicant]
Invitation to Pay Additional Fees for PCT/US2015/044387, mailed Jan. 28, 2016. [cited by applicant]
Invitation to Pay Additional Fees for PCT/US2017/040722, mailed Oct. 18, 2017. [cited by applicant]
Partial Supplementary European Search Report for EP 15829427.2, mailed Feb. 8, 2018. [cited by applicant]
Altarejos et al., “CREB and the CRTC co-activators: sensors for hormonal and metabolic signals,” Nat Rev Mol Cell Biol. Mar. 2011;12(3):141-51. doi: 10.1038/nrm3072. [cited by applicant]
Ananieva et al., “The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling,” Nat Immunol. Sep. 2008;9(9):1028-36. doi: 10.1038/ni.1644. [cited by applicant]
Antiga et al., “Serum levels of the regulatory cytokines transforming growth factor-β and interleukin-10 are reduced in patients with discoid lupus erythematosus,” Lupus, May 2011;20(6):556-60. doi: 10.1177/096120331039… [cited by applicant]
Armstrong et al., “The epidemiology of UV induced skin cancer,” J Photochem Photobiol B., Oct. 2001;63(1-3):8-18. [cited by applicant]
Baertschi et al., “Class I and IIa histone deacetylases have opposite effects on sclerostin gene regulation,” J Biol Chem., Sep. 5, 2014;289(36):24995-5009. doi: 10.1074/jbc.M114.564997. Epub Jul. 10, 2014. [cited by applicant]
Bain et al., “The selectivity of protein kinase inhibitors: a further update,” Biochem J., Dec. 15, 2007;408(3):297-315. [cited by applicant]
Baron et al., “WNT signaling in bone homeostasis and disease: from human mutations to treatments,” Nat Med., Feb. 2013;19(2):179-92. doi: 10.1038/nm.3074. Epub Feb. 6, 2013. [cited by applicant]
Benoit et al., “Macrophage polarization in bacterial infections,” J Immunol., Sep. 15, 2008;181(6):3733-9. [cited by applicant]
Berdeaux et al., “SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes,” Nat Med., May 2007;13(5):597-603. Epub Apr. 29, 2007. [cited by applicant]
Bergwitz et al., “Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23,” Annu Rev Med., 2010;61:91-104. doi: 10.1146/annurev.med.051308.111339. [cited by applicant]
Bertolotto et al., “Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes,” J Cell Biol., Aug. 10, 1998;142(3):827-35. [cited by applicant]
Bettencourt-Dias et al., “Genome-wide survey of protein kinases required for cell cycle progression,” Nature, Dec. 23, 2004;432(7020):980-7. [cited by applicant]
Bonewald et al., “The amazing osteocyte,” J Bone Miner Res., Feb. 2011;26(2):229-38. doi: 10.1002/jbmr.320. [cited by applicant]
Bonnet et al., “Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin,” Proc Natl Acad Sci USA, Sep. 11, 2012;109(37):15048-53. doi: 10.1073/pnas.12… [cited by applicant]
Bos et al., “The 500 Dalton rule for the skin penetration of chemical compounds and drugs,” Exp Dermatol., Jun. 2000;9(3):165-9. [cited by applicant]
Bouxsein et al., “Guidelines for assessment of bone microstructure in rodents using micro-computed tomography,” J Bone Miner Res., Jul. 2010;25(7):1468-86. doi: 10.1002/jbmr.141. [cited by applicant]
CAPLUS Accession No. 1999:764041, 5 pages, Dobrusin et al., “Preparation of oxopyrido- and -pyrimidopyrimidines as cellular proliferation inhibitors.” [cited by applicant]
CAPLUS Accession No. 2000:291041, 11 pages, Harris et al., “Preparation of pyrimidopyrimidinones as T-cell tyrosine kinase inhibitors.” [cited by applicant]
CAPLUS Accession No. 2004:412945, 5 pages, Luk et al., “Preparation of pyrimido Src tyrosine kinase inhibitors as anti-proliferative agents for the treatment of cancer.” [cited by applicant]
CAPLUS Accession No. 2005:120672, 22 pages, Sim et al., “Preparation of pyrimidopyrimidines as protein kinase inhibitors.” [cited by applicant]
CAPLUS Accession No. 2006:333232, 17 pages, Engh et al., “Preparation of amide derivatives of 3-phenyl-dihydropyrimido[4,5-d]pyrimidinones as antitumor agents.” [cited by applicant]
CAPLUS Accession No. 2007:1363959, 4 pages, Ren et al., “Preparation of pyrimidopyrimidinones and analogs as FGF receptor kinases inhibitors.” [cited by applicant]
CAPLUS Accession No. 2011:391484, 1 page, Kuglstatter et al., “Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures.” [cited by applicant]
CAPLUS Accession No. 2012:1191791, 1 page, Wan et al., “Discovery of novel Bruton's tyrosine kinase inhibitors using a hybrid protocol of virtual screening approaches based on SVM model, pharmacophore and molecular dock… [cited by applicant]
CAPLUS Accession No. 2012:1816780, 5 pages, Ding et al., “Pyrimidopyrimidone derivatives as EGFR inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancers.” [cited by applicant]
CAPLUS Accession No. 2012:1832180, 2 pages, Ding et al., “Pyrimidopyrimidone derivatives as EGFR inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancers.” [cited by applicant]
CAPLUS Accession No. 2012:235081, 3 pages, Chang et al., “Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine790® Methionine… [cited by applicant]
CAPLUS Accession No. 2013:1609048, 10 pages, Xu et al., “Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5 d]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhib… [cited by applicant]
CAPLUS Accession No. 2013:51064, 2 pages, Zender et al., “Pharmaceutical compositions comprising sorafenib in combination with MAPK14 inhibitors for the treatment and prevention of liver cancer.” [cited by applicant]
CAPLUS Accession No. 2013:82305, 2 pages, Zender et al., “Pharmaceutical compositions comprising sorafenib in combination with MAPK14 inhibitors for the treatment and prevention of liver cancer.” [cited by applicant]
CAPLUS Accession No. 2014:1558688, 10 pages, D'Agostino et al., “Preparation of heteroaryl compounds as inhibitors of protein kinases.” [cited by applicant]
CAPLUS Accession No. 2014:1753550. 1 page. Huang et al., DFG-out Mode of Inhibition by an Irreversible Type-1 Inhibitor Capable of Overcoming Gate-Keeper Mutations. [cited by applicant]
CAPLUS Accession No. 2014:1815213, 3 pages, Tan et al., “Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.” [cited by applicant]
CAPLUS Accession No. 2015:453874, 12 pages, Ding et al., “Pyrimido-heterocyclic compounds as EGFR protease inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer.” [cited by applicant]
CAPLUS Accession No. 2015:690395, 2 pages, Reynolds et al., “N-Aryl-heteroarylamines as FGFR4 inhibitors and their Preparation.” [cited by applicant]
CAPLUS Accession No. 2015:76117, 2 pages, Gray et al., “Preparation of functionalized pyrimidine compounds as kinase inhibitors for the treatment of proliferative diseases.” [cited by applicant]
Chang et al., “Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development,” Mol Cell Biol., Oct. 2004;24(19):8467-76. [cited by applicant]
Cheloha et al., “PTH receptor-1 signaling-mechanistic insights and therapeutic prospects,” Nat Rev Endocrinol., Dec. 2015;11(12):712-24. doi: 10.1038/nrendo.2015.139. Epub Aug. 25, 2015. [cited by applicant]
Choi et al., “A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl,” J. Med. Chem., 2010, vol. 53, pp. 5439-5448. [cited by applicant]
Clark et al., “Novel cross-talk within the IKK family controls innate immunity,” Biochem J., Feb. 15, 2011;434(1):93-104, doi: 10.1042/BJ20101701. [cited by applicant]
Clark et al., “Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages,” Proc Natl Acad Sci USA, Oct. 16, 2012;109(42):16986-91, doi: 10.10… [cited by applicant]
Clark et al., “The TRAF-associated protein TANK facilitates cross-talk within the IkappaB kinase family during Toll-like receptor signaling,” Proc Natl Acad Sci USA, Oct. 11, 2011;108(41):17093-8. doi: 10.1073/pnas.1114… [cited by applicant]
Clark et al., “Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation,” … [cited by applicant]
Collette et al., “Targeted deletion of Sost distal enhancer increases bone formation and bone mass,” Proc Natl Acad Sci USA, Aug. 28, 2012;109(35):14092-7. doi: 10.1073/pnas.1207188109. Epub Aug. 10, 2012. [cited by applicant]
Cui et al., “Central role of p53 in the suntan response and pathologic hyperpigmentation,” Cell, Mar. 9, 2007;128(5):853-64. [cited by applicant]
Cummings et al., “Denosumab for prevention of fractures in postmenopausal women with osteoporosis,” N Engl J Med., Aug. 20, 2009;361(8):756-65. doi: 10.1056/NEJMoa0809493. Epub Aug. 11, 2009. [cited by applicant]
Dempster et al., Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. Jan. 2013;28(1):2-17. doi: 10… [cited by applicant]
Dentin et al., “Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2,” Nature, Sep. 20, 2007;449(7160):366-9. Epub Sep. 5, 2007. [cited by applicant]
D'Orazio et al., “Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning,” Nature, Sep. 21, 2006;443(7109):340-4. [cited by applicant]
Ewald et al., “Nucleic acid sensing Toll-like receptors in autoimmunity,” Curr Opin Immunol., Feb. 2011;23(1):3-9. doi: 10.1016/j.coi.2010.11.006. Epub Dec. 14, 2010. [cited by applicant]
Eyers et al., “Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution,” Chem Biol., Jun. 1998;5(6):321-8. [cited by applicant]
Fitzgerald et al., “IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway,” Nat Immunol., May 2003;4(5):491-6. [cited by applicant]
Fleming et al., “Regulatory macrophages: setting the threshold for therapy,” Eur J Immunol., Sep. 2011;41(9):2498-502. doi: 10.1002/eji.201141717. [cited by applicant]
Fraser et al., “Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo,” Exp Hematol., Dec. 2009;37(12):1435-44. doi: 10.1016/j.exphem.2009.09.007. Epub Sep. 26, 2009. [cited by applicant]
Fu et al., “Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer,” Mol Cell Biol., Sep. 2006;26(17):6453-68. [cited by applicant]
Fu et al., “Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein,” J Biol Chem., Dec. 13,… [cited by applicant]
Fulzele et al., “Myelopoiesis is regulated by osteocytes through Gsα-dependent signaling,” Blood, Feb. 7, 2013;121(6):930-9. doi: 10.1182/blood-2012-06-437160. Epub Nov. 16, 2012. [cited by applicant]
Galli et al., “Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass,” Endocrinology, Jan. 2008;149(1):146… [cited by applicant]
Garcia-Gomez et al., “Dasatinib as a bone-modifying agent:anabolic and antiresorptive effects,” PLoS One. 2012;7(4):e34914. doi:10.1371/journal.pone.0034914. Epub Apr. 23, 2012. [cited by applicant]
Gandini et al., “Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors,” Eur J Cancer., Sep. 2005;41(14):2040-59. [cited by applicant]
Ghoreschi et al., “Janus kinases in immune cell signaling,” Immunol Rev., Mar. 2009;228(1):273-87. doi: 10.1111/j.1600-065X.2008.00754.x. [cited by applicant]
Grozinger et al., “Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization,” Proc Natl Acad Sci USA, Jul. 5, 2000;97(14):7835-40. [cited by applicant]
Haberland et al., “Regulation of HDAC9 gene expression by MEF2 establishes a negative-feedback loop in the transcriptional circuitry of muscle differentiation,” Mol Cell Biol., Jan. 2007;27(2):518-25. Epub Nov. 13, 2006. [cited by applicant]
Haberland et al., “The many roles of histone deacetylases in development and physiology: implications for disease and therapy,” Nat Rev Genet., Jan. 2009;10(1):32-42. doi: 10.1038/nrg2485. [cited by applicant]
Hadgraft et al., “The selection and design of topical and transdermal agents: a review,” J Investig Dermatol Symp Proc., Aug. 1998;3(2):131-5. [cited by applicant]
Hahn et al., “Targeted therapies in systemic lupus erythematosus: successes, failures and future,” Ann Rheum Dis., Mar. 2011;70 Suppl 1:i64-i66. doi: 10.1136/ard.2010.142208. [cited by applicant]
Harms et al., “Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone,” Photochem Photobiol., Nov.-Dec. 2009;85(6):1434-9. doi: 10.1111/j.175… [cited by applicant]
Hart et al., “SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies,” Leukemia, Nov. 2011;25(11):1751-9. doi: 10.1038/leu.2011.148. Epub Jun. 21, 2011. [cited by applicant]
Hemmi et al., “The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection,” J Exp Med., Jun. 21, 2004;199(12):1641-50. [cited by applicant]
Henriksson et al., “SIK2 regulates CRTCs, HDAC4 and glucose uptake in adipocytes,” J Cell Sci., Feb. 1, 2015;128(3):472-86. [cited by applicant]
Henriksson et al., “The AMPK-related kinase SIK2 is regulated by cAMP via phosphorylation at Ser358 in adipocytes,” Biochem J., Jun. 15, 2012;444(3):503-14. doi: 10.1042/BJ20111932. [cited by applicant]
Heppner et al., “Immune attack: the role of inflammation in Alzheimer disease,” Nat Rev Neurosci., Jun. 2015;16(6):358-72. doi: 10.1038/nrn3880. [cited by applicant]
Horike et al., “Downregulation of SIK2 expression promotes the melanogenic program in mice,” Pigment Cell Melanoma Res., Dec. 2010;23(6):809-19. doi: 10.1111/j.1755-148X.2010.00760.x. Epub Aug. 31, 2010. [cited by applicant]
Jansson et al., “Glucose controls CREB activity in islet cells via regulated phosphorylation of TORC2,” Proc Natl Acad Sci USA, Jul. 22, 2008;105(29):10161-6, doi:10.1073/pnas.0800796105. Epub Jul. 14, 2008. [cited by applicant]
Kantarjian et al., “Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia,” N Engl J Med., Jun. 17, 2010;362(24):2260-70. [cited by applicant]
Kawai et al., “The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors,” Nat Immunol., May 2010;11(5):373-84. doi: 10.1038/ni.1863. Epub Apr. 20, 2010. [cited by applicant]
Keller et al., “SOST is a target gene for PTH in bone,” Bone, Aug. 2005;37(2):148-58. [cited by applicant]
Kennedy et al., “The influence of painful sunburns and lifetime sun exposure on the risk of actinic keratoses, seborrheic warts, melanocytic nevi, atypical nevi, and skin cancer,” J Invest Dermatol. Jun. 2003;120(6):108… [cited by applicant]
Khaled et al., “Control of melanocyte differentiation by a MITF-PDE4D3 homeostatic circuit,” Genes Dev., Oct. 15, 2010;24(20):2276-81. doi: 10.1101/gad.1937710. [cited by applicant]
Kim et al., “Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers,” Mol Cell Biol., Sep. 2006;26(17):6469-86. [cited by applicant]
Kim et al., “An essential role for histone deacetylase 4 in synaptic plasticity and memory formation,” J Neurosci., Aug. 8, 2012;32(32):10879-86. doi: 10.1523/JNEUROSCI.2089-12.2012. [cited by applicant]
Kim et al., “Transcriptional control of receptor activator of nuclear factor-kappaB ligand by the protein kinase A activator forskolin and the transmembrane glycoprotein 130-activating cytokine, oncostatin M, is exerted… [cited by applicant]
Kir et al., “Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia,” Nature, Sep. 4, 2014;513(7516):100-4. doi: 10.1038/nature13528. Epub Jul. 13, 2014. [cited by applicant]
Kobayashi et al., “Supranuclear melanin caps reduce ultraviolet induced DNA photoproducts in human epidermis,” J Invest Dermatol., May 1998;110(5):806-10. [cited by applicant]
Kopf et al., “Averting inflammation by targeting the cytokine environment,” Nat Rev Drug Discov., Sep. 2010;9(9):703-18. doi: 10.1038/nrd2805. [cited by applicant]
Kozhemyakina et al., “Parathyroid hormone-related peptide represses chondrocyte hypertrophy through a protein phosphatase 2A/histone deacetylase 4/MEF2 pathway,” Mol Cell Biol., Nov. 2009;29(21):5751-62. doi: 10.1128/MC… [cited by applicant]
Kramer et al., “Mef2c deletion in osteocytes results in increased bone mass,” J Bone Miner Res., Feb. 2012;27(2):360-73. doi: 10.1002/jbmr.1492. [cited by applicant]
Kramer et al., “Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice,” J Bone Miner Res., Feb. 2010;25(2):178-89. doi: 10.1359/jbmr.090730. [cited by applicant]
Kronenberg et al., “Developmental regulation of the growth plate,” Nature, May 15, 2003;423(6937):332-6. [cited by applicant]
Kuhn et al., “Interleukin-10-deficient mice develop chronic enterocolitis,” Cell, Oct. 22, 1993;75(2):263-74. [cited by applicant]
Kumagai et al., “A potent inhibitor of SIK2, 3, 3′, 7-trihydroxy-4′-methoxyflavon (4′-O-methylfisetin), promotes melanogenesis in B16F10 melanoma cells,” PLoS One, 2011;6(10):e26148. doi: 10.1371/journal.pone.0026148. E… [cited by applicant]
Kunisada et al., “Murine cutaneous mastocytosis and epidermal melanocytosis induced by keratinocyte expression of transgenic stem cell factor,” J Exp Med., May 18, 1998;187(10):1565-73. [cited by applicant]
Langendonk et al., “Afamelanotide for Erythropoietic Protoporphyria,” N Engl J Med., Jul. 2, 2015;373(1):48-59. doi: 10.1056/NEJMoa1411481. [cited by applicant]
Leupin et al., “Control of the SOST bone enhancer by PTH using MEF2 transcription factors,” J Bone Miner Res., Dec. 2007;22(12):1957-67. [cited by applicant]
Li et al., “Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression,” Ann NY Acad Sci., Jan. 2016;1364:62-73. doi: 10.1111/nyas.12750. Epub Apr. 2, 2015. [cited by applicant]
Liang et al., “Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5(3-trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent Selective, and Orally Available BCR-ABL… [cited by applicant]
Liu et al., “Engineering Src family protein kinases with unnatural nucleotide specificity,” Chem Biol., Feb. 1998;5(2):91-101. [cited by applicant]
Liu et al., “Salt-inducible kinase is involved in the regulation of corticotropin-releasing hormone transcription in hypothalamic neurons in rats,” Endocrinology, Jan. 2012;153(1):223-33. doi: 10.1210/en.2011-1404. Epub… [cited by applicant]
Lizcano et al., “LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1,” EMBO J., Feb. 25, 2004;23(4):833-43. Epub Feb. 19, 2004. [cited by applicant]
Loots et al., “Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease,” Genome Res., Jul. 2005;15(7):928-35. Epub Jun. 17, 2005. [cited by applicant]
Lu et al., “DMP1-targeted Cre expression in odontoblasts and osteocytes,” J Dent Res., Apr. 2007;86(4):320-5. [cited by applicant]
Maier et al., “Development of N-4,6-pyrimidine-N-alkyl-N′-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase,” Bioorg Med Chem Lett., Jul. 15, 2006;16(14):3646-50. Epub May 8, 2006. [cited by applicant]
Mair et al., “Lifespan extension induced by AMPK and calcineurin is mediated by CRTC-1 and CREB,” Nature, Feb. 17, 2011;470(7334):404-8. doi: 10.1038/nature09706. [cited by applicant]
Mallinson et al., “Macrocycles in new drug discovery,” Future Med Chem., Jul. 2012;4(11):1409-38. doi: 10.4155/fmc.12.93. [cited by applicant]
Manthey et al., “JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases… [cited by applicant]
Martin et al., “Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity,” J Med Chem., Aug. 10, 2006;49(16):4981-91. [cited by applicant]
Martowicz et al., “The mouse RANKL gene locus is defined by a broad pattern of histone H4 acetylation and regulated through distinct distal enhancers,” J Cell Biochem., Aug. 2011;112(8):2030-45. doi: 10.1002/jcb.23123. [cited by applicant]
Mcclung et al., “Romosozumab in postmenopausal women with low bone mineral density,” N Engl J Med., Jan. 30, 2014;370(5):412-20. doi: 10.1056/NEJMoa1305224. Epub Jan. 1, 2014. [cited by applicant]
Mckinsey et al., “Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation,” Nature, Nov. 2, 2000;408(6808):106-11. [cited by applicant]
Mcnulty et al., “Hydrophilic Interaction Chromatography Reduces the Complexity of the Phosphoproteome and Improves Global Phosphopeptide Isolation and Detection,” Mol Cell Proteomics, May 2008;7(5):971-80. doi: 10.1074/… [cited by applicant]
Mcwhirter et al., “IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts,” Proc Natl Acad Sci USA, Jan. 6, 2004;101(1):233-8. Epub Dec. 16, 2003. [cited by applicant]
Mosser et al., “Interleukin-10: new perspectives on an old cytokine,” Immunol Rev., Dec. 2008;226:205-18. doi: 10.1111/j.1600-065X.2008.00706.x. [cited by applicant]
Nakashima et al., “Evidence for osteocyte regulation of bone homeostasis through RANKL expression,” Nat Med., Sep. 11, 2011;17(10):1231-4. doi: 10.1038/nm.2452. [cited by applicant]
Navarro et al., “Phosphoproteomic analysis reveals an intrinsic pathway for the regulation of histone deacetylase 7 that controls the function of cytotoxic T lymphocytes,” Nat Immunol., Apr. 2011;12(4):352-61. doi: 10.1… [cited by applicant]
Newton et al., “Activation of the cAMP pathway by variant human MC1R alleles expressed in HEK and in melanoma cells,” Peptides, Oct. 2005;26(10):1818-24. [cited by applicant]
Oancea et al., “TRPM1 forms ion channels associated with melanin content in melanocytes,” Sci Signal., May 12, 2009;2(70):ra21. doi: 10.1126/scisignal.2000146. [cited by applicant]
Obri et al., “HDAC4 integrates PTH and sympathetic signaling in osteoblasts,” J Cell Biol., Jun. 23, 2014;205(6):771-80. doi: 10.1083/jcb.201403138. Epub Jun. 16, 2014. [cited by applicant]
O'Garra et al., “Strategies for use of IL-10 or its antagonists in human disease,” Immunol Rev., Jun. 2008;223:114-31. doi: 10.1111/j.1600-065X.2008.00635.x. [cited by applicant]
Onal et al., “Deletion of the Distal Tnfsf11 RL-D2 Enhancer That Contributes to PTH-Mediated RANKL Expression in Osteoblast Lineage Cells Results in a High Bone Mass Phenotype in Mice,” J Bone Miner Res., Feb. 2016;31(2… [cited by applicant]
Pacifici et al., “Role of T cells in the modulation of PTH action: physiological and clinical significance,” Endocrine, Dec. 2013;44(3):576-82. doi: 10.1007/s12020-013-9960-8. Epub Jun. 2, 2013. [cited by applicant]
Park et al., “A long-term time course of colorimetric evaluation of ultraviolet light-induced skin reactions,” Clin Exp Dermatol., Jul. 1999;24(4):315-20. [cited by applicant]
Park et al., “SIK2 is critical in the regulation of lipid homeostasis and adipogenesis in vivo,” Diabetes, Nov. 2014;63(11):3659-73. doi: 10.2337/db13-1423. Epub Jun. 4, 2014. [cited by applicant]
Parra et al., “Regulatory signal transduction pathways for class IIa histone deacetylases,” Curr Opin Pharmacol., Aug. 2010;10(4):454-60. doi: 10.1016/j.coph.2010.04.004. Epub May 4, 2010. [cited by applicant]
Patel et al., “The LKB1-salt-inducible kinase pathway functions as a key gluconeogenic suppressor in the liver,” Nat Commun., Aug. 4, 2014;5:4535. doi: 10.1038/ncomms5535. [cited by applicant]
Pennello et al., “Association of surface ultraviolet B radiation levels with melanoma and nonmelanoma skin cancer in United States blacks,” Cancer Epidemiol Biomarkers Prev., Mar. 2000;9(3):291-7. [cited by applicant]
Perry et al., “Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection,” J Exp Med., Jun. 21, 2004;199(12):1651-8. [cited by applicant]
Pethe et al., “A chemical genetic screen in [cited by applicant]
Pfeifer et al., “Mutations induced by ultraviolet light,” Mutat Res., Apr. 1, 2005;571(1-2):19-31. Epub Jan. 20, 2005. [cited by applicant]
Popov et al., “Lack of salt-inducible kinase 2 (SIK2) prevents the development of cardiac hypertrophy in response to chronic high-salt intake,” PLoS One, Apr. 21, 2014;9(4):e95771. doi: 10.1371/journal.pone.0095771. eCo… [cited by applicant]
Price et al., “alpha-Melanocyte-stimulating hormone signaling regulates expression of microphthalmia, a gene deficient in Waardenburg syndrome,” J Biol Chem., Dec. 4, 1998;273(49):33042-7. [cited by applicant]
Ran et al., “Genome engineering using the CRISPR-Cas9 system,” Nat. Protoc., Nov. 2013.;8(11):2281-308, DOI:10.1038/nprot.2013.143. Epub Oct. 24, 2013. [cited by applicant]
Rhee et al., “PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling,” J Bone Miner Res., May 2011;26(5):1035-46. doi: 10.1002/jbmr.304. [cited by applicant]
Saidak et al., “Low-dose PTH increases osteoblast activity via decreased Mef2c/Sost in senescent osteopenic mice,” J Endocrinol., Oct. 2014;223(1):25-33. doi: 10.1530/JOE-14-0249. Epub Jul. 23, 2014. [cited by applicant]
Saini et al., “Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH,” J Biol Chem., Jul. 12, 2013;288(28):20122-34. doi: … [cited by applicant]
Sakamaki et al., “Role of the SIK2-p35-PJA2 complex in pancreatic β-cell functional compensation,” Nat Cell Biol., Mar. 2014;16(3):234-44. doi: 10.1038/ncb2919. [cited by applicant]
Santegoets et al., “Toll-like receptors in rheumatic diseases: are we paying a high price for our defense against bugs?” FEBS Lett., Dec. 1, 2011;585(23):3660-6. doi: 10.1016/j.febslet.2011.04.028. Epub Apr. 16, 2011. [cited by applicant]
Saraiva et al., “The regulation of IL-10 production by immune cells,” Nat Rev Immunol., Mar. 2010;10(3):170-81. doi: 10.1038/nri2711. Epub Feb. 15, 2010. [cited by applicant]
Sasagawa et al., “SIK3 is essential for chondrocyte hypertrophy during skeletal development in mice,” Development, Mar. 2012;139(6):1153-63. doi: 10.1242/dev.072652. Epub Feb. 8, 2012. [cited by applicant]
Sasaki et al., “SIK2 is a key regulator for neuronal survival after ischemia via TORC1-CREB,” Neuron., Jan. 13, 2011;69(1):106-19. doi: 10.1016/j.neuron.2010.12.004. [cited by applicant]
Screaton et al., “The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector,” Cell, Oct. 1, 2004;119(1):61-74. [cited by applicant]
Sharma et al., “Triggering the interferon antiviral response through an IKK-related pathway,” Science, May 16, 2003;300(5622):1148-51. Epub Apr. 17, 2003. [cited by applicant]
Shimizu et al., “HDAC4 represses matrix metalloproteinase-13 transcription in osteoblastic cells, and parathyroid hormone controls this repression,” J Biol Chem., Mar. 26, 2010;285(13):9616-26. doi: 10.1074/jbc.M109.094… [cited by applicant]
Soriano et al., “Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice,” Cell, Feb. 22, 1991;64(4):693-702. [cited by applicant]
Spatz et al., “The Wnt Inhibitor Sclerostin Is Up-regulated by Mechanical Unloading in Osteocytes in Vitro,” J Biol Chem., Jul. 3, 2015;290(27):16744-58. doi: 10.1074/jbc.M114.628313. Epub May 7, 2015. [cited by applicant]
St John et al., “Analysis of SOST expression using large minigenes reveals the MEF2C binding site in the evolutionarily conserved region (ECR5) enhancer mediates forskolin, but not 1,25-dihydroxyvitamin D3 or TGFβ1 resp… [cited by applicant]
Sundberg et al., “Development of Chemical Probes for Investigation of Salt-Inducible Kinase Function in Vivo,” ACS Chem Biol., Aug. 19, 2016;11(8):2105-11. doi: 10.1021/acschembio.6b00217. Epub Jun. 6, 2016. [cited by applicant]
Sundberg et al., “Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells,” Proc Natl Acad Sci USA, Aug. 26, 2014;111(3… [cited by applicant]
Takemori et al., “Inactivation of HDAC5 by SIK1 in AICAR-treated C2C12 myoblasts,” Endocr J., 2009;56(1):121-30. Epub Oct. 22, 2008. [cited by applicant]
Taniguchi et al., “Histone deacetylase 5 limits cocaine reward through cAMP-induced nuclear import,” Neuron., Jan. 12, 2012;73(1):108-20. doi: 10.1016/j.neuron.2011.10.032. [cited by applicant]
Tella et al., “Prevention and treatment of postmenopausal osteoporosis,” J Steroid Biochem Mol Biol., Jul. 2014;142:155-70. doi:10.1016/j.jsbmb.2013.09.008. Epub Oct. 29, 2013. [cited by applicant]
Triantafillidis et al., “Current and emerging drugs for the treatment of inflammatory bowel disease,” Drug Des Devel Ther., Apr. 6, 2011;5:185-210. doi: 10.2147/DDDT.S11290. [cited by applicant]
Tsai et al., “Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial,” Lancet, Jul. 6, 2013;382(9886):50-6. doi:10.1016/S0140-6736(13)60856-9. Epub May … [cited by applicant]
Tsatmalia et al., “Skin POMC peptides. Their binding affinities and activation of the human MC1 receptor,” Ann NY Acad Sci., Oct. 20, 1999;885:466-9. [cited by applicant]
Tu et al., “Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading,” Bone, Jan. 2012;50(1):209-17. doi: 10.1016/j.bone.2011.10.025. Epub Oct. 30, 2011. [cited by applicant]
Valverde et al., “Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans,” Nat Genet., Nov. 1995;11(3):328-30. [cited by applicant]
Wakamatsu et al., “Advanced chemical methods in melanin determination,” Pigment Cell Res., Jun. 2002;15(3):174-83. [cited by applicant]
Walkinshaw et al., “The tumor suppressor kinase LKB1 activates the downstream kinases SIK2 and SIK3 to stimulate nuclear export of class IIa histone deacetylases,” J Biol Chem., Mar. 29, 2013;288(13):9345-62. doi: 10.10… [cited by applicant]
Wan et al., “Discovery of Novel Bruton's Tyrosine Kinase Inhibitors Using a Hybrid Protocol of Virtual Screening Approaches Based on SVM Model, Pharmacophore and Molecular Docking,” Chem. Biol. Drug. Des., 2012, vol. 80… [cited by applicant]
Wang et al., “Cloning of a novel kinase (SIK) of the SNF1/AMPK family from high salt diet-treated rat adrenal,” FEBS Lett., Jun. 18, 1999;453(1-2):135-9. [cited by applicant]
Wang et al., “A hormone-dependent module regulating energy balance,” Cell, May 13, 2011;145(4):596-606. doi: 10.1016/j.cell.2011.04.013. [cited by applicant]
Wein et al., “HDAC5 controls MEF2C-driven sclerostin expression in osteocytes,” J Bone Miner Res., Mar. 2015;30(3):400-11. doi: 10.1002/jbmr.2381. [cited by applicant]
Weir et al., “Targeted overexpression of parathyroid hormone-related peptide in chondrocytes causes chondrodysplasia and delayed endochondral bone formation,” Proc Natl Acad Sci USA, Sep. 17, 1996;93(19):10240-5. [cited by applicant]
Wu et al., “Cumulative ultraviolet radiation flux in adulthood and risk of incident skin cancers in women,” Br J Cancer., Apr. 2, 2014;110(7):1855-61. doi: 10.1038/bjc.2014.43. Epub Mar. 4, 2014. [cited by applicant]
Wu et al., “Exploring the selectivity of PI3Kα and mTOR inhibitors by 3D-QSAR, molecular dynamics simulations and MM/GBSA binding free energy decomposition,” Med Chem Commun., 2013;4:1482-1496. DOI: 10.1039/C3MD00157A. [cited by applicant]
Wu et al., “Gsα enhances commitment of mesenchymal progenitors to the osteoblast lineage but restrains osteoblast differentiation in mice,” J Clin Invest., Sep. 2011;121(9):3492-504. doi: 10.1172/JCI46406. Epub Aug. 1, … [cited by applicant]
Xiong et al., “Matrix-embedded cells control osteoclast formation,” Nat Med., Sep. 11, 2011;17(10):1235-41. doi: 10.1038/nm.2448. [cited by applicant]
Yahara et al., “Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice by inhibiting Sik3,” Nat Commun., Mar. 24, 2016;7:10959. doi: 10.1038/ncomms10959. [cited by applicant]
Yang et al., “CBP/p300-interacting protein CITED1 modulates parathyroid hormone regulation of osteoblastic differentiation,” Endocrinology, Apr. 2008;149(4):1728-35. doi: 10.1210/en.2007-0826. Epub Jan. 10, 2008. [cited by applicant]
Yasumoto et al., “Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene,” Mol Cell Biol., Dec. 1994;14(12):8058-70. [cited by applicant]
Xu et al., Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties… [cited by applicant]